{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T19:47:14Z","timestamp":1769975234946,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.vaccine.2013.02.059","type":"journal-article","created":{"date-parts":[[2013,3,19]],"date-time":"2013-03-19T09:01:14Z","timestamp":1363683674000},"page":"2387-2394","source":"Crossref","is-referenced-by-count":13,"title":["A nationwide surveillance of invasive pneumococcal disease in adults in Israel before an expected effect of PCV7"],"prefix":"10.1016","volume":"31","author":[{"given":"Gili","family":"Regev-Yochay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galia","family":"Rahav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Strahilevitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihad","family":"Bishara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Katzir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Chowers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Finkelstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bibiana","family":"Chazan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oren","family":"Zimhony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Dagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2013.02.059_bib0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/thx.2009.129502","article-title":"Clinical and economic burden of community-acquired pneumonia among adults in Europe","volume":"67","author":"Welte","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.vaccine.2013.02.059_bib0010","doi-asserted-by":"crossref","first-page":"759","DOI":"10.7326\/0003-4819-60-5-759","article-title":"Pneumococcal bacteremia with Especial Reference to Bacteremic Pneumococcal Pneumonia","volume":"60","author":"Austrian","year":"1964","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2013.02.059_bib0015","unstructured":"Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010;59(34):1102\u20136 [Epub 2010\/09\/04]."},{"issue":"18","key":"10.1016\/j.vaccine.2013.02.059_bib0020","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1056\/NEJMoa022678","article-title":"Effectiveness of pneumococcal polysaccharide vaccine in older adults","volume":"348","author":"Jackson","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2013.02.059_bib0025","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/648593","article-title":"Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine","volume":"201","author":"Pilishvili","year":"2010","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2013.02.059_bib0030","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1086\/652440","article-title":"The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes","volume":"50","author":"Lehmann","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2013.02.059_bib0035","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1086\/651680","article-title":"Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine use in an American Indian population at high risk for disease","volume":"50","author":"Weatherholtz","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"49","key":"10.1016\/j.vaccine.2013.02.059_bib0040","doi-asserted-by":"crossref","first-page":"9123","DOI":"10.1016\/j.vaccine.2011.10.009","article-title":"Streptococcus pneumoniae serotypes in Utah adults at the end of the PCV7 era","volume":"29","author":"Kendall","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2013.02.059_bib0045","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF03404065","article-title":"The epidemiology of invasive pneumococcal disease in British Columbia following implementation of an infant immunization program: increases in herd immunity and replacement disease","volume":"103","author":"Sahni","year":"2012","journal-title":"Can J Public Health"},{"issue":"2","key":"10.1016\/j.vaccine.2013.02.059_bib0050","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/infdis\/jir730","article-title":"Impact of more than a decade of pneumococcal conjugate vaccine use on carriage and invasive potential in Native American communities","volume":"205","author":"Scott","year":"2012","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2013.02.059_bib0055","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1086\/594125","article-title":"Epidemiology of invasive pneumococcal disease among adult patients in barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997\u20132007","volume":"48","author":"Ardanuy","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2013.02.059_bib0060","article-title":"Incidence of pneumococcal infections among children under 15 years in southern Catalonia throughout the heptavalent conjugate vaccine era, 2002\u20132009","author":"Vila-Corcoles","year":"2012","journal-title":"Infection"},{"issue":"12","key":"10.1016\/j.vaccine.2013.02.059_bib0065","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/j.vaccine.2006.11.065","article-title":"Invasive pneumococcal disease epidemiology and effectiveness of 23-valent pneumococcal polysaccharide vaccine in Alaska native adults","volume":"25","author":"Singleton","year":"2007","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2013.02.059_bib0070","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/cid\/cir326","article-title":"Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States","volume":"53","author":"Rosen","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2013.02.059_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-144-1-200601030-00004","article-title":"Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization","volume":"144","author":"Flannery","year":"2006","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.vaccine.2013.02.059_bib0080","doi-asserted-by":"crossref","first-page":"43","DOI":"10.5694\/j.1326-5377.2008.tb01897.x","article-title":"Invasive pneumococcal disease in Indigenous people in north Queensland: an update, 2005\u20132007","volume":"189","author":"Hanna","year":"2008","journal-title":"Med J Aust"},{"issue":"10","key":"10.1016\/j.vaccine.2013.02.059_bib0085","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1473-3099(11)70090-1","article-title":"Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study","volume":"11","author":"Miller","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2013.02.059_bib0090","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jinf.2009.07.004","article-title":"Trends in invasive pneumococcal disease among older adults in Olmsted County, Minnesota","volume":"59","author":"Tsigrelis","year":"2009","journal-title":"J Infect"},{"issue":"46","key":"10.1016\/j.vaccine.2013.02.059_bib0095","doi-asserted-by":"crossref","first-page":"6600","DOI":"10.1016\/j.vaccine.2012.08.012","article-title":"Rapid reduction in invasive pneumococcal disease after introduction of PCV7 into the National Immunization Plan in Israel","volume":"30","author":"Ben-Shimol","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.02.059_bib0100","article-title":"Impact of the emergence of non-vaccine pneumococcal serotypes on the clinical presentation and outcome of adults with invasive pneumococcal pneumonia","author":"Burgos","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"31","key":"10.1016\/j.vaccine.2013.02.059_bib0105","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1016\/j.vaccine.2009.04.057","article-title":"Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany","volume":"27","author":"Ruckinger","year":"2009","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2013.02.059_bib0110","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jinf.2011.08.013","article-title":"Incidence of invasive pneumococcal disease among elderly people in Southern Catalonia, Spain, 2002\u20132009: an increase in serotypes not contained in the heptavalent conjugate vaccine","volume":"63","author":"Ochoa-Gondar","year":"2011","journal-title":"J Infect"},{"issue":"2","key":"10.1016\/j.vaccine.2013.02.059_bib0115","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/aje\/kwr058","article-title":"New approaches to estimating national rates of invasive pneumococcal disease","volume":"174","author":"Costa","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"3","key":"10.1016\/j.vaccine.2013.02.059_bib0120","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jinf.2009.12.008","article-title":"Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: England and Wales, 1996\u20132006","volume":"60","author":"Trotter","year":"2010","journal-title":"J Infect"},{"issue":"12","key":"10.1016\/j.vaccine.2013.02.059_bib0125","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/j.vaccine.2011.12.119","article-title":"Pneumococcal disease in South Australia: vaccine success but no time for complacency","volume":"30","author":"Johnson","year":"2012","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2013.02.059_bib0130","doi-asserted-by":"crossref","first-page":"e1000081","DOI":"10.1371\/journal.pmed.1000081","article-title":"Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study","volume":"6","author":"Harboe","year":"2009","journal-title":"PLoS Med"},{"issue":"9","key":"10.1016\/j.vaccine.2013.02.059_bib0135","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1097\/INF.0b013e3182624a40","article-title":"Eradication of invasive pneumococcal disease due to the seven-valent pneumococcal conjugate vaccine serotypes in Calgary, Alberta","volume":"31","author":"Leal","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.vaccine.2013.02.059_bib0140","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/MD.0b013e31821a5a76","article-title":"Factors predicting mortality in invasive pneumococcal disease in adults in Alberta","volume":"90","author":"Marrie","year":"2011","journal-title":"Medicine"},{"issue":"34","key":"10.1016\/j.vaccine.2013.02.059_bib0145","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1016\/j.vaccine.2011.05.099","article-title":"Invasive pneumococcal disease: association between serotype, clinical presentation and lethality","volume":"29","author":"Rodriguez","year":"2011","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2013.02.059_bib0150","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1086\/655828","article-title":"Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis","volume":"51","author":"Weinberger","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2013.02.059_bib0155","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1086\/374624","article-title":"Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential","volume":"187","author":"Brueggemann","year":"2003","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2013.02.059_bib0160","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1086\/423820","article-title":"Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children","volume":"190","author":"Brueggemann","year":"2004","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2013.02.059_bib0165","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1086\/499242","article-title":"Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen","volume":"42","author":"Sjostrom","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2013.02.059_bib0170","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1086\/313609","article-title":"The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II","volume":"30","author":"Hausdorff","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2013.02.059_bib0175","doi-asserted-by":"crossref","unstructured":"Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61:816\u20139 [Epub 2012\/10\/12].","DOI":"10.1111\/ajt.12073"},{"key":"10.1016\/j.vaccine.2013.02.059_bib0180","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/cis700","article-title":"Pneumococcal polysaccharide vaccine efficacy and routine use of conjugate vaccines in infants: there is no need for a vaccine program in older adults at present","author":"Truck","year":"2012","journal-title":"Clin Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1300248X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1300248X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T02:06:16Z","timestamp":1595556376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1300248X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":36,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0264410X1300248X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.02.059","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}